Assertio Holdings (ASRT) Operating Income (2019 - 2026)
Assertio Holdings' (ASRT) quarterly Operating Income came in at -$18.5 million in Q1 2026, down 39.58% year-on-year from -$30.6 million in Q1 2025, and down 57.2% quarter-over-quarter from -$11.7 million in Q4 2025.
Assertio Holdings (ASRT) Operating Income (2019 - 2026) Analysis & Trends
Assertio Holdings has disclosed Operating Income across 8 years of filings, most recently posting -$18.5 million for Q1 2026.
- Operating Income for Q1 2026 came in at -$18.5 million, down 39.58% year-over-year; the trailing twelve-month figure through Mar 2026 was -$26.8 million (up 19.77% YoY), and the FY2025 annual result was -$21.5 million, up 12.01% from the prior year.
- Operating Income came in at -$18.5 million for Q1 2026 at Assertio Holdings, down from -$11.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $12.4 million in Q2 2023 to a low of -$228.3 million in Q3 2023.
- The 5-year median for Operating Income is -$3.6 million (2024), against an average of -$15.8 million.
- Across the five-year window, Operating Income plunged 3647.89% in 2023 and surged 476.57% in 2025, its largest moves.
- Assertio Holdings' Operating Income stood at $10.6 million in 2022, then tumbled by 404.36% to -$32.3 million in 2023, then surged by 58.32% to -$13.5 million in 2024, then climbed by 12.8% to -$11.7 million in 2025, then slumped by 57.2% to -$18.5 million in 2026.
- The last three Operating Income figures came in at -$18.5 million (Q1 2026), -$11.7 million (Q4 2025), and $11.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 652.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 833.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 325.80 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 14.03 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 193.40 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 307.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -48.28 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -78.32 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 81.33 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn | -18.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.47 Mn |
| Dec 31, 2025 | -11.75 Mn |
| Sep 30, 2025 | 11.48 Mn |
| Jun 30, 2025 | -8.04 Mn |
| Mar 31, 2025 | -13.23 Mn |
| Dec 31, 2024 | -13.47 Mn |
| Sep 30, 2024 | -3.05 Mn |
| Jun 30, 2024 | -3.62 Mn |
| Mar 31, 2024 | -4.34 Mn |
| Dec 31, 2023 | -32.33 Mn |
| Sep 30, 2023 | -228.27 Mn |
| Jun 30, 2023 | 12.42 Mn |
| Mar 31, 2023 | 4.64 Mn |
| Dec 31, 2022 | 10.62 Mn |
| Sep 30, 2022 | 6.43 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 11.56 Mn |
| Dec 31, 2021 | 7.98 Mn |
| Sep 30, 2021 | 5.93 Mn |
| Jun 30, 2021 | -12.00 Mn |